Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma

Cancer Cell International

Yuqin Song¹  Ning Ding¹  Chen Zhang¹  Lijuan Deng¹  Lingyan Ping¹  Meifeng Tu¹  Ningjing Lin¹  Xiaopei Wang¹  Yan Xie¹  Zhitao Ying¹  Weiping Liu¹  Wen Zheng¹  Jun Zhu¹  Zhiying Fu¹ 

[1] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China

关键词: Efficacy;    Safety;    DLBCL;    Bevacizumab;   

Others  :  792444
DOI  :  10.1186/1475-2867-14-5

 received in 2013-08-26, accepted in 2014-01-16,  发布年份 2014

【 摘 要 】

Background

Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma (DLBCL), a common sub-type of non-Hodgkin lymphoma. But 40% – 50% of DLBCL patients cannot be cured by this regimen. Some clinical trials showed that bevacizumab might be useful in the treatment of DLBCL. This study evaluated the safety and efficacy of bevacizumab combined with the R-CHOP (A-R-CHOP) regimen in Chinese patients with previously untreated DLBCL.

Methods

Patients with previously untreated DLBCL received A-R-CHOP regimen therapy. All patients with complete response (CR)/ unconfirmed complete response(CRu) after 8 cycles of A-R-CHOP received the bevacizumab maintenance therapy once every 3 weeks. The remained bulky disease was treated with radiotherapy.

Results

Seven Chinese patients were treated. All of them had bulky diseases. One patient had progressive disease after 4 cycles of A-R-CHOP therapy. The rest six patients completed 8 cycles of A-R-CHOP treatment. All of these six patients reached CR/CRu (5 CR, 1 CRu). Bevacizumab maintenance therapy was given to 4 CR patients. All 7 patients experienced Grade 3/4 hematologic adverse events; additionally, one had Grade 3 gastrointestinal toxicity and one had Grade 1 epistaxis. During bevacizumab maintenance therapy, one patient had Grade 1 gingival bleeding, another experienced Grade 1 proteinuria and then Grade 3 congestive heart failure 4 months after completion of maintenance therapy. At the end of July 2013, the patient who had progressive disease after 4 cycles of A-R-CHOP died of progressive disease, the other six remained CR response.

Conclusions

The A-R-CHOP regimen is effective for untreated DLBCL, but may cause bevacizumab-specific toxicities, which should be monitored.

【 授权许可】

   
2014 Fu et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008. Int J Cancer 2010, 127:2293-2917.
• [2]Tilly H, Drey LM, ESMO Guidelines Working Group: Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:172-174.
• [3]Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA: Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013, 87(2):146-171.
• [4]Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010, 116(12):2040-2045.
• [5]Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL): Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116.
• [6]Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera InternationalTrial (MInT) Group: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial Group. Lancet Oncol 2011, 2:1013-1022.
• [7]Potti A, Ganti AK, Kargas S, Koch M: Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res 2002, 22:2899-2901.
• [8]Mori F, Ishida T, Ito A, Sato F, Masaki A, Takino H, Ri M, Kusumoto S, Komatsu H, Ueda R, Inagaki H, Iida S: Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. Blood Cancer J 2012, 2(4):e67.
• [9]Ruan J, Hajjar K, Rafii S, Leonard JP: Angiogenesis and antiangiogenic therapy in non-Hodgkin’s lymphoma. Ann Oncol 2009, 20:413-424.
• [10]Stopeck AT, Bellamy W, Unger J, Rimsza L, Iannone M, Fisher RI, Miller TP: Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin’s lymphoma (NHL): Southwest Oncology Group Study S0108. J Clin Oncol 2005, 23(16S):6592.
• [11]Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP: A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group Study S0108. Leuk Lymphoma 2009, 50:728-735.
• [12]Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, Li S, Weller EA, Orazi A, Horning SJ: Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006, 47:998-1005.
• [13]Swerdlow S, Campo E, Harris NL (Eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue In International Agency for Research on Cancer. Geneva, Switzerland: World Health Organization; 2008.
• [14]Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP: Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999, 17:2351-2352.
• [15]Common Terminology Criteria for Adverse Events v3.0 (CTCAE). : ; 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf webcite Accessed July 30, 2013
• [16]Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U: Safety of bevacizumab in patients with advanced cancer:a meta-analysis of randomized controlled trial. Oncologist 2010, 15(12):1179-1191.
• [17]Ganjoo K, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ, Habermann TM, Kahl BS, Advani RH: Bevacizumab and CHOP (a-CHOP) in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative group study (E2404). Leuk Lymphomain press
• [18]Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP: A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood 2012, 120:1210-1217.
• [19]Hapani S, Sher A, Chu D, Wu S: Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010, 79:27-38.
• [20]Miles D: Management of toxicity in patients receiving therapy with bevacizumab. EJC 2008, 6:9-39.
• [21]Wu S, Kim C, Baer L, Zhu X: Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010, 21:1381-1389.
• [22]Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Eng J Med 2008, 358(11):1129-1136.
• [23]Cheng H, Force T: Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010, 106(1):21-34.
• [24]Kamba T, McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96(12):1788-1795.
• [25]Vaklavas C, Lenihan D, Kurarock R, Tsimberidou AM: Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 2010, 15:130-141.
• [26]Hawkes EA, Okines AF, Plummer C, Cunningham D: Cardiotoxicity in patients treated with bevacizumab is potentially reversible. J Clin Oncol 2011, 29:560-562.